SAREPTA THERAPEUTICS INC | 28,733 Euro | +1,137 +4,12 % | |
| WKN: A1J1BH ISIN: US8036071004 Ticker-Symbol: AB3A | Frankfurt | 20.05.13 | 14:56 Uhr |
Branche BiotechnologieAktienmarkt NASDAQ Biotech |
|
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 10.05. | Sarepta Therapeutics to Present Company Overview at Upcoming Conferences / Webcast Accessible via Sarepta Therapeutics Website | 32 | Marketwired | |
| CAMBRIDGE, MA -- (Marketwired) -- 05/10/13 -- Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the following... Mehr lesen zu: Sarepta Therapeutics to Present Company Overview at Upcoming Conferences / Webcast Accessible via Sarepta Therapeutics Website | ||||
| 10.05. | Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin | 10 | The Street | |
| 09.05. | Sarepta Therapeutics' CEO Discusses Q1 2013 Results - Earnings Call Transcript | 3 | Seeking Alpha | |
| 09.05. | Sarepta up as CEO says he's 'encouraged' on accelerated approval | 2 | bizjournals | |
| 09.05. | Sarepta's Meaningless Q1 Results | 3 | Motley Fool | |
| 09.05. | Sarepta Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | |
| 09.05. | Sarepta Therapeutics Announces First Quarter 2013 Financial Results and Recent Corporate Developments / Documents Requested by FDA for Accelerated Approval Consideration of Eteplirsen Will Be Submitted This Month; Clinical, Regulatory, and Manufacturing | 23 | Marketwired | |
| CAMBRIDGE, MA -- (Marketwired) -- 05/09/13 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today reported financial results for the three months ended... Mehr lesen zu: Sarepta Therapeutics Announces First Quarter 2013 Financial Results and Recent Corporate Developments / Documents Requested by FDA for Accelerated Approval Consideration of Eteplirsen Will Be Submitted This Month; Clinical, Regulatory, and Manufacturing | ||||
| 07.05. | Sarepta Therapeutics Initiates Dosing in Phase I Multiple Ascending Dose Study of Drug for Treatment of Marburg Virus | 32 | Marketwired | |
| CAMBRIDGE, MA -- (Marketwired) -- 05/07/13 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced that it has initiated dosing in a Phase 1... Mehr lesen zu: Sarepta Therapeutics Initiates Dosing in Phase I Multiple Ascending Dose Study of Drug for Treatment of Marburg Virus | ||||
| 26.04. | Sarepta Therapeutics to Announce First Quarter 2013 Financial Results and Corporate Update on May 9, 2013 | 84 | Marketwired | |
| CAMBRIDGE, MA -- (Marketwired) -- 04/26/13 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report first quarter financial results before the NASDAQ... Mehr lesen zu: Sarepta Therapeutics to Announce First Quarter 2013 Financial Results and Corporate Update on May 9, 2013 | ||||
| 26.04. | Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail! | 22 | The Street | |
| 25.04. | Sarepta Therapeutics: Irrational Exuberance | 11 | Seeking Alpha | |
| 19.04. | Sarepta Therapeutics, Inc. - 8-K, Departure of Directors or Certain Officers; Election of ... | 14 | SEC Filings | |
| 18.04. | Sarepta Therapeutics to Present Company Overview at the Needham Annual Healthcare Conference / Webcast Accessible via Sarepta Therapeutics Website | 38 | Marketwired | |
| CAMBRIDGE, MA -- (Marketwired) -- 04/18/13 -- Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the Needham &... Mehr lesen zu: Sarepta Therapeutics to Present Company Overview at the Needham Annual Healthcare Conference / Webcast Accessible via Sarepta Therapeutics Website | ||||
| 17.04. | Sarepta: What's Going On? | 12 | Seeking Alpha | |
| 17.04. | Why Sarepta Is A Good Buy With Or Without Accelerated Approval | 5 | Seeking Alpha | |
| 17.04. | Sarepta Vs Glaxo In The Race To Treat Muscular Dystrophy | 9 | Seeking Alpha | |
| 17.04. | Sarepta Therapeutics CEO Discusses Update on FDA's Consideration of Accelerated Approval for Eteplirsen After Further Review of Data on Dystrophin and Clinical Outcomes (Transcript) | 8 | Seeking Alpha | |
| 16.04. | Why Sarepta Therapeutics Shares Tumbled | 10 | Motley Fool | |
| 16.04. | Mid-Day Market Update: Grainger Gains On Upbeat Earnings, Sarepta Dips | 3 | Benzinga.com | |
| 16.04. | A Key Exchange On Sarepta Therapeutics' Promising Muscular Dystrophy Drug | 1 | Forbes | |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| EVOTEC | 2,81 | -0,28 % | Evotec: Kurs der Aktie hat weiteres Potenzial |
| MEDIGENE | 0,96 | +2,45 % | Medigene-Aktie feiert Studienergebnisse mit EndoTAG |
| VICAL | 2,752 | -0,18 % | Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma |
| DISCOVERY LABORATORIES | 1,146 | -0,17 % | Discovery Labs Announces Completion of $14.25 Million Public Offering |
| EPIGENOMICS | 1,89 | -1,05 % | Epigenomics AG: Ergebnisse der Vergleichsstudie zwischen Epigenomics Epi proColon(R) und FIT werden auf der Digestive Disease Week vorgestellt |
